Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have lost about 0.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion. Analysts surveyed by Visible Alpha were looking for $4.19 and $2.83 billion, ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 15 years ago, it would be worth $1,256.99 today based on a ...

The stock's fall snapped a four-day winning streak.